This post has expired! It was posted more than 90 days ago.
<- Back

140579 - Type 2 Diabetes (T2D): Evaluating Emerging Insulin Therapies

  • : Online

Through case studies, this program covers the clinical application of the newer insulin products and their impact on hypoglycaemia. While some of the therapies and combinations may not be available currently in Australia, they have been included here for a comprehensive review.

Relevance to General Practice

Type 2 diabetes (T2D) is a progressive disease and it is increasingly recognised that most patients eventually require insulin therapy initiation at some point in the course of treatment. 

With new formulations of insulin providing improved glycaemic efficacy whilst minimising hypoglycaemia and glycaemic variability, it is important to stay abreast of the evolution of insulin therapies to optimise patient care through basal insulin initiation, through bolus insulin intensification, to the use of premix and basal insulin plus glucagon-like peptide-1 receptor agonist fixed-ratio combinations.

Learning outcomes
  • Differentiate new rapid and long acting basal analogues from older agents and their impact on hypoglycaemia and glucose variability
  • Know when and how to switch from one insulin to another
  • Assess the benefit of emerging fixed-ratio combinations of basal-insulin plus GLP-1R agonist
  • Delivery
    140579 - Type 2 Diabetes (T2D): Evaluating Emerging Insulin Therapies
    Provider Type
    Education Provider
    1 hour
    Start Date
    End Date
    CPD Points
    1 hour
    Contact Phone
    Log in into view this field.